BR112014024793A2 - método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica. - Google Patents

método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica.

Info

Publication number
BR112014024793A2
BR112014024793A2 BR112014024793A BR112014024793A BR112014024793A2 BR 112014024793 A2 BR112014024793 A2 BR 112014024793A2 BR 112014024793 A BR112014024793 A BR 112014024793A BR 112014024793 A BR112014024793 A BR 112014024793A BR 112014024793 A2 BR112014024793 A2 BR 112014024793A2
Authority
BR
Brazil
Prior art keywords
masp
inhibiting agent
complement activation
dependent complement
inhibiting
Prior art date
Application number
BR112014024793A
Other languages
English (en)
Inventor
A Demopulos Gregory
Schwaeble Hans-Wilhelm
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of BR112014024793A2 publication Critical patent/BR112014024793A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica em um aspecto, a invenção fornece métodos e composições para inibir a ativação do complemento dependente de masp-3 em um indivíduo sofrendo de hemoglobinúria paroxística noturna pela administração ao indivíduo de uma composição que compreende uma quantidade de um agente inibidor da masp-3 em uma quantidade eficaz para inibir a ativação do complemento dependente de masp-3. em outro aspecto, a invenção fornece métodos e composições para aumentar a sobrevivência das hemácias em um indivíduo que sofre de hemoglobinúria paroxística noturna pela administração ao indivíduo de uma composição que compreende uma quantidade de pelo menos um de um agente inibidor da masp-1 e/ou um agente inibidor da masp-3 eficaz para aumentar a sobrevivência das hemácias. em algumas modalidades, é administrado ao indivíduo um agente inibidor da masp-2 e um agente inibidor da masp-1, um agente inibidor da masp-2 e um agente inibidor da masp-3, um agente inibidor da masp-3 e um agente inibidor da masp-1 ou um agente inibidor da masp-1, um agente inibidor da masp-2 e um agente inibidor da masp-3.
BR112014024793A 2012-04-06 2013-04-05 método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica. BR112014024793A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261621461P 2012-04-06 2012-04-06
PCT/US2013/035488 WO2013180834A2 (en) 2012-04-06 2013-04-05 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Publications (1)

Publication Number Publication Date
BR112014024793A2 true BR112014024793A2 (pt) 2019-08-27

Family

ID=49325295

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014024793A BR112014024793A2 (pt) 2012-04-06 2013-04-05 método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica.

Country Status (29)

Country Link
US (3) US20130273053A1 (pt)
EP (2) EP2833907B1 (pt)
JP (3) JP6366571B2 (pt)
KR (2) KR102142508B1 (pt)
CN (1) CN104661676A (pt)
AU (3) AU2013267909B2 (pt)
BR (1) BR112014024793A2 (pt)
CA (2) CA3087933A1 (pt)
CL (1) CL2014002694A1 (pt)
CY (1) CY1120736T1 (pt)
DK (2) DK3366307T3 (pt)
ES (2) ES2670668T3 (pt)
HK (1) HK1206996A1 (pt)
HR (1) HRP20180671T1 (pt)
HU (1) HUE036930T2 (pt)
IL (2) IL234991B (pt)
IN (1) IN2014KN02324A (pt)
LT (1) LT2833907T (pt)
MX (2) MX357540B (pt)
NO (1) NO2881536T3 (pt)
NZ (2) NZ781091A (pt)
PL (2) PL3366307T3 (pt)
PT (1) PT2833907T (pt)
RS (1) RS57266B1 (pt)
RU (2) RU2655299C2 (pt)
SI (1) SI2833907T1 (pt)
TR (1) TR201806939T4 (pt)
WO (1) WO2013180834A2 (pt)
ZA (1) ZA201408100B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
RU2709351C2 (ru) * 2012-06-18 2019-12-17 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
WO2014144542A2 (en) * 2013-03-15 2014-09-18 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
CN110177875B (zh) * 2016-11-28 2023-11-28 中外制药株式会社 包含抗原结合结构域和运送部分的多肽
WO2018186322A1 (en) * 2017-04-03 2018-10-11 Chugai Seiyaku Kabushiki Kaisha Anti-masp-1 antibodies and methods of use
KR20210016545A (ko) * 2018-05-29 2021-02-16 오메로스 코포레이션 Masp-2 억제제 및 사용 방법
MX2022001268A (es) * 2019-07-31 2022-02-22 Biocryst Pharm Inc Regimenes de dosificacion para inhibidores orales del factor d del complemento.
AU2020398241A1 (en) 2019-12-04 2022-06-30 Omeros Corporation MASP-2 inhibitors and methods of use
CN114295594B (zh) * 2021-12-06 2023-09-19 贵州理工学院 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
JP2003515338A (ja) * 1999-12-02 2003-05-07 クリスチャン イェンセニウス，イェンス 補体結合酵素、ｍａｓｐ−３、及びその使用
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) * 2001-07-23 2006-05-09 Intel Corporation Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
CA2490007C (en) 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US20070253949A1 (en) * 2004-02-03 2007-11-01 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
ATE419671T1 (de) * 2006-07-31 2009-01-15 Fiat Ricerche Durch eine fluidströmung betätigbarer elektrischer generator
ES2628973T3 (es) 2007-05-31 2017-08-04 University Of Washington Mutagénesis inducible de genes diana
PE20110926A1 (es) * 2008-09-26 2011-12-29 Roche Glycart Ag Anticuerpos biespecificos anti-egfr/anti-igf-1r
JP2013516389A (ja) * 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
US20120022543A1 (en) * 2009-03-05 2012-01-26 Smith & Nephew, Inc. System, method, and apparatus for locating a femoral neck guide wire
KR101870378B1 (ko) * 2009-07-17 2018-06-25 릭스하스피탈렛 보체 활성화의 억제제로서의 ｍａｓｐ 이소형
WO2011057158A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
ES2683307T3 (es) 2011-04-08 2018-09-26 University Of Leicester Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2

Also Published As

Publication number Publication date
EP3366307B1 (en) 2021-07-28
NO2881536T3 (pt) 2018-06-30
CL2014002694A1 (es) 2015-08-28
ES2670668T3 (es) 2018-05-31
JP2021001199A (ja) 2021-01-07
ES2894944T3 (es) 2022-02-16
RU2014144621A (ru) 2016-05-27
RU2018114903A3 (pt) 2021-08-12
AU2013267909A1 (en) 2014-11-27
WO2013180834A2 (en) 2013-12-05
LT2833907T (lt) 2018-06-11
RU2018114903A (ru) 2019-03-04
HK1206996A1 (en) 2016-01-22
IL234991B (en) 2020-06-30
US20190382505A1 (en) 2019-12-19
US20220242972A1 (en) 2022-08-04
PT2833907T (pt) 2018-05-29
NZ727063A (en) 2021-10-29
PL2833907T3 (pl) 2018-08-31
AU2018200721A1 (en) 2018-02-22
IL234991A0 (en) 2014-12-31
WO2013180834A3 (en) 2014-04-03
US20130273053A1 (en) 2013-10-17
MX2014012045A (es) 2015-05-15
TR201806939T4 (tr) 2018-06-21
CA2869326C (en) 2021-09-21
IL274721A (en) 2020-07-30
DK2833907T3 (en) 2018-05-28
AU2018200721B2 (en) 2020-03-26
MX357540B (es) 2018-07-13
KR102142508B1 (ko) 2020-08-10
PL3366307T3 (pl) 2022-03-07
EP2833907A4 (en) 2016-03-16
KR102318623B1 (ko) 2021-11-02
MX2018008658A (es) 2021-10-19
HUE036930T2 (hu) 2018-08-28
CN104661676A (zh) 2015-05-27
KR20150003785A (ko) 2015-01-09
JP2018162307A (ja) 2018-10-18
CA3087933A1 (en) 2013-12-05
EP2833907A2 (en) 2015-02-11
HRP20180671T1 (hr) 2018-07-13
DK3366307T3 (da) 2021-11-01
AU2013267909B2 (en) 2018-03-01
EP2833907B1 (en) 2018-02-28
KR20200097808A (ko) 2020-08-19
CY1120736T1 (el) 2019-12-11
ZA201408100B (en) 2022-05-25
JP6815355B2 (ja) 2021-01-20
RU2655299C2 (ru) 2018-05-24
AU2020204163A1 (en) 2020-07-09
EP3366307A1 (en) 2018-08-29
NZ781091A (en) 2022-04-29
JP6366571B2 (ja) 2018-08-01
JP2015514117A (ja) 2015-05-18
IN2014KN02324A (pt) 2015-05-01
IL274721B (en) 2022-04-01
SI2833907T1 (en) 2018-07-31
CA2869326A1 (en) 2013-12-05
RS57266B1 (sr) 2018-08-31
NZ629675A (en) 2017-02-24

Similar Documents

Publication Publication Date Title
BR112014024793A2 (pt) método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica.
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
BR112016014271A2 (pt) composições tópicas em gel incluindo polímero de poli(monoestearoil glicerol-co-succi¬nato) e métodos para aprimorar a aplicação tópica de um agente de benefício
BR112015021352A2 (pt) composições antimicrobianas
BR112016008409A2 (pt) Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
PH12015501783B1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
BR112012019921A2 (pt) composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório.
AR091706A1 (es) Formulaciones de laquinimod sin agentes alcalinizantes
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
BR112013019394A2 (pt) uso de um agente
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112016026470A8 (pt) composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
EA201791525A3 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.